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Numerous	studies	worldwide	are	aimed	on	the	develop­
ment	of	immunotherapy	to	target	and	remove	tumor	cells	
as	well	as	substances	such	as	immunopotentiators,	immu­
noinitiators	and	biological	response	modificators	that	act	to	
prevent	carcinogenesis	and	induce	carcinostasis	[1].	The	
use	of	medicinal	mushrooms	in	the	fight	against	cancer	is	
known	for	a	very	long	time	in	Korea,	China,	Japan,	Russia,	
USA	and	Canada.	Higher	basidiomycetes	belong	to	the	
group	of	immunoceuticals	by	their	mode	of	action.	More	
than	650	mushrooms	species	have	yielded	potential	im­
munoceuticals	that	exhibit	anticancer	activity	in vitro	or	in	
animal	models	[2–4].	Medicinal	mushrooms	represent	an	
unlimited	source	of	potent	new	pharmaceutical	products.	
Many,	if	not	all,	medicinal	mushrooms	contain	biologically	
active	substances	in	fruit	bodies,	cultured	mycelium,	cul­
ture	broth	that	 include	hemicellulose,	polysaccharides,	
lipopolysaccharides,	peptides,	proteins,	glycoproteins,	
nucleosides,	 triterpenoids,	complex	starches,	 lectins,	
lipid	derivatives	and	other	metabolites	which	have	been	
classified	as	molecules	with	potent	immunomodulatory,	
anticancer,	anti­proliferative,	anti­inflammatory,	antiviral,	
hypotensive	and	antithrombotic	activities	[5–8].	Unique	
biotherapeutic	medicines	such	as	Lentinan,	Krestin,	
Schizophyllan,	Sonifilan,	Ganoderan,	Grifolan,	Pleuran	
and	others	were	prepared	and	studied	 in	experiment	
investigations	and	clinical	trials	[1,	6,	7].
Recent	studies	have	demonstrated	that	unmethy­
lated	CpG	motifs	 that	are	present	 in	bacterial	DNA	
or	 synthetic	deoxyoligonucleotides	exhibit	 potent	
immunostimulatory	effects	 [9].	 The	ability	of	CpG	
DNA	to	activate	vigorously	the	cells	of	innate	immune	
system	and	indirectly	to	augment	adaptive	immunity	
advantage	the	successful	use	of	CpG	DNA	as	a	potent	
immunoadjuvant	in	immunotherapy	of	infectious	disea­
ses,	allergy	and	cancer	[9–12].
Although	in	large	part	studied	bioactive	substances	
isolated	from	medicinal	mushrooms	are	polysaccha­
rides	or	 their	derivates,	we	aim	 to	study	mushroom	
DNA	containing	unmethylated	CpG	motifs	with	pro­
bably	immunomodulatory	and	antitumor	activities.	The	
aim	of	present	pilot	study	was	to	isolate	DNA	from	fruit	
body	of	edible	mushroom	Pleurotus ostreatus	and	to	
research	 immunostimulatory	activity	and	antitumor	
potential	of	mushroom	DNA.
MATERIALS AND METHODS
Isolation and analysis of mushroom DNA.	
P. ostreatus	which	belongs	to	higher	Basidiomycetes	
was	used.	Genomic	DNA	was	isolated	from	fresh	fruit	
bodies	of	P. ostreatus	using	a	standardized	DNA	extrac­
tion	protocol	[13].	Concentration	of	isolated	DNA	was	
estimated	by	spectrophotometry.	Pulsed­field	agarose	
gel	(PFAG)	electrophoresis	[14]	was	used	for	identifica­
tion	of	DNA	in	the	samples.	To	detect	the	presence	of	
unmethylated	CG­dinucleotides,	 restriction	analysis	
with	endonuclease	Hpa	II	(Sigma,	USA)	[15]	according	
to	 the	 instructions	of	 the	manufacturer	with	 the	next	
PFAG	electrophoresis	 followed	by	ethidium	bromide	
staining	was	performed	[16].	For	DNase	experiments,	
DNA	prerarations	were	digested	with	50	μg/ml	DNase	I	
(Sigma,	USA)	 for	2	h	 in	10	mM	MgCl2,	50	mM	Tris	
(pH	7.5).	Isolated DNA was dissolved in 0.15 M endo­	 	 	 	 	 	 	
toxin	free	phosphatebuffersaline (P�S)at theconcent­	 	 	 	 	 	
ration	of	1	mg/ml.	DNA	samples	were	stored	at	–20	°С.	
Repeated	freezing	of	DNA	samples	was	avoided.	
Animals and tumor model.	In	the	study,	age	and	
sex­matched	�AL�/c	mice	(9–12	weeks	old)	obtained	
from	vivarium	of	R.E.	Kavetsky	Institute	of	Experimental	
Pathology,	Oncology	and	Radiobiology	NAS	of	Ukraine	
(Kyiv,	Ukraine)	were	used.	The	animals	were	housed	in	
standard	facilities,	with	free	access	to	water	and	food.	
All	animals	were	maintained	under	strict	ethical	condi­
tions	according	to	International	recommendations.
Murine	Ehrlich	carcinoma	transplanted	 intraperi­
toneally	 to	�AL�/c	mice	has	been	used	as	a	 tumor	
model.	Tumor	cell	suspensions	in	physiological	saline	
were	ordinarily	prepared	 from	 tumor	cells	of	ascitic	
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transplantable	Ehrlich	carcinoma	 to	 the	 final	 con­
centration	of	1.25	х	106	cells/ml;	and	then	inoculated	
subcutaneously	 into	 right	 flank	with	2.5	х	105	viable	
tumor	cells/mouse	in	0.2	ml	(on	day	0).
In vitro NK activity assay. Splenic	mononuclear	
cells	 (MNC)	were	obtained	as	previously	described	
[11].	MNC	were	cultured	in	RPMI­1640	medium	(Sig­
ma,	USA)	supplemented	with	10%	heat­inactivated	
fetal	calf	serum	(Sigma,	USA),	penicillin	(40	U/ml)	(Kyiv­
medpreparat,	Ukraine)	and	streptomycin	(40	μg/ml)	
(Kyivmedpreparat,	Ukraine).	The	final	concentration	of	
MNC	was	7.5	х	106	cells/ml.	MNC	were	preincubated	
with	0.05,	0.5	and	5.0	μg/ml	of	DNA	for	2	h	at	37	°C	in	
humidified	air	with	5%	CO2,	washed	by	centrifugation	
and	used	 for	cytotoxicity	assay.	Phorbol	myristate	
acetate	 (PMA;	Sigma,	USA)	at	 the	concentration	of	
250	ng/ml	was	used	 for	MNC	stimulation.	The	via­
bility	 of	 the	effector	 cells	 after	preincubation	with	
mushroom	DNA	was	determined	by	the	conventional	
trypan	blue	dye	exclusion	test	and	was	not	less	than	
99%.	Ascitic	 transplantable	Ehrlich	carcinoma	cells	
isolated	from	peritoneal	cavity	of	�AL�/c	8–9	weeks	
old	mice	at	11th	day	were	used	as	NK­resistant	target	
cells	 for	nonspecific	cytotoxicity	assay. Tumor cells	 	 	
were	suspended	in	culture	medium	so	that	the	con­
centration	of	cells	was	about	2.5	х	106	cells/ml.	Cell	
number	and	viability	(about	98%)	were	determined	in	
microscopical	supravital	 test	with	 trypan	blue.	Non­
specific	cytotoxicity test was performed according to	 	 	 	 	 	
[11].	Cytotoxic	activity	of	NK	cells	was	expressed	as	
cytotoxicity	index	(CI,	%).
In vivo studies.	At	 the	2nd	day	after	 tumor	cells	
inoculation	mice	were	treated	by	intraperitoneal	injec­
tions	of	0.1	ml	the	mushroom	CpG	DNA	(100	μg/ml	in	
P�S)	at	the	dosage	of	10	μg/mouse;	such	injections	
were	repeated	triply	with	3	day	 intervals.	At	preven­
tive	 therapy,	mice	were	 treated	by	 the	similar	sche­
dule.	At	the	8th	day	after	the	preventive	therapy	was	
completed,	 tumor	cells	of	ascitic	Ehrlich	carcinoma	
(2.5	 х	 105	 cells/mouse)	were	 inoculated	 subcuta­
neously	to	treated	mice.	The	control	group	composed	
of	 9	mice	 (survival	 data	of	 two	control	 subgroups	
(for	therapeutic	and	prophylactic)	were	summarized	
because	difference	was	considered	as	insignificant)	
was	treated	with	P�S.
The	antitumor	efficacy	of	therapy	and	preventive	
treatment	by	P. ostreatus DNA	was	evaluated	using	
increase	 in	host`s	 life	span.	Percentage	 increase	 in	
life	span	(%	ILS)	was	calculated	as:
																MSTT	–	MSTC%	ILS	=	————————	х	100%,																						MSTC
where	MSTT	—	median	 survival	 time	of	 treated	
mice,	MSTC	—	median	survival	time	in	control	group	
(untreated	mice).
MST	was	calculated	on	the	basis	of	mortality	data.
Statistical analysis.	All	 in vitro	data	were	from	at	
least	 three	 independent	experiments.	All	 in vivo	ex­
periments	were	performed	twice.	Survival	curves	were	
constructed	by	using	the	Kaplan­Meyer	method.	For	sta­
tistical	analysis,	two­tailed	Studentʹs	t­test	was	applied.	
p	values	<	0.05	were	considered	as	significant.	Statistical	
analyses	were	performed	using	one­way	ANOVA.
RESULTS AND DISCUSSION
Mushroom	DNA	from	fresh	fruit	bodies	of	P. ost­
reatus	was	routinely	isolated	(the	260/280	coefficient	
was	1.8–1.85).	Native	 isolated	mushroom	DNA	was	
visualized	using	PAAG	electrophoresis	 followed	by	
ethidium	bromide	staining	(at	the	 left	on	Fig.	1).	No	
protein	contamination	was	registered.
Fig. 1. Restriction	analysis	of	DNA	isolated	from	fruit	body	of	
mushroom	P. ostreatus	using	Hpa	II	endonuclease
Early	immunostimulatory	effects	of	bacterial	DNA	
were	shown	to	be	mainly	due	to	a	specific	sequence	of	
CpG	motifs	presented	in	the	unmethylated	state	and	
occur	at	a	higher	frequency	than	in	mammalian	DNA	
[9].	Therefore,	the	content	of	these	immunostimulatory	
DNA	sequences	and	level	of	methylation	of	cytosine	
residues	 in	such	CpG	motifs	can	be	considered	as	
screening	factors	of	DNA­containing	substances	as	
potential	 candidates	 for	 immunotherapy	of	cancer	
and	other	diseases.	To	determine	 the	 level	of	 un­
methylated	CG­dinucleotides	 in	 isolated	mushroom	
DNA,	 restriction	analysis	with	endonuclease	Нра	 ІІ	
was	applied	[15].	As	shown	in	Fig.	1, P. ostreatus	DNA	
demonstrated	moderate	sensitivity	to	Hpa	II.	Earlier	it	
was	demonstrated	that	isolated	DNA­containing	frac­
tion	from	culture	medium	after	the	8th	day	of	cultivation	
of	Bacillus subtilis	 strain	7025	and	B. subtilis	 strain	
GP1­807­03	(on	the	9th	day),	showed	high	sensitivity	
to	НраІІ,	that	proves	the	fact	of	relatively	high	content	
of	unmethylated	СG­dinucleotides	in	isolated	DNA	se­
quences	[17].	Furthermore,	the	sensitivity	of	B. subtilis 
DNA	 to	HpaII	correlated	with	 its immunostimulatory	
and	anticancer	activity	 [11].	At	 the	same	 time,	DNA	
from	chicken	eryhrocytes	was	 relatively	 resistant	 to	
Hpa	II	[17]	and	demonstrated	low	immunostimulatory	
activity	[18].
Activation	of	NK	cytotoxicity	was	the	first	effect	of	
CpG	DNA	that	was	described	[19].	Other	studies	also	
have	demonstrated	augmentation	of	NK	cell	activity	by	
DNA	containing	unmethylated	CpG­dinucleotides	in vit­
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ro	or	in vivo [11,	20].	We	have	studied	the	concentration­
dependent	effect	in vitro	of	mushroom	DNA	on	cytotoxic	
activity	of	NK	cells	(Fig.	2).	Increase	of	NK	cytotoxicity	
was	observed	when	murine	splenic	MNC	were	 incu­
bated	with	mushroom	DNA	at	the	concentration	of	0.05	
and	0.5	μg/ml	while	at	the	concentration	of	5.0	μg/ml	
P. ostreatus	DNA	showed	none	 immunostimulatory	
effect.	It	is	important	to	note	that	stimulatory	effect	of	
mushroom	DNA	on	NK	cell	cytotoxicity	was	comparable	
with	 that	when	standard	stimulant	of	 lymphoid­mac­
rophage	 lines,	PMA,	was	used.	To	demonstrate	 that	
stimulation	resulted	from	mushroom	DNA	rather	than	
contaminants	such	as	polysaccharides,	we	performed	
experiments	using	DNA	preparations	which	had	been	
digested	by	DNase	I.	As	shown	in	Fig.	2,	pretreatment	
of	the	mushroom	DNA	by	DNase	I	completely	abrogates	
the	activation	of	NK	cell	cytotoxicity.
Fig. 2. Augmentation	of	NK	cell	activity	after	preincubation	of	
murine	MNC	with	different	concentrations	of	P. ostreatus DNA	
(TC	—	tumors	celles)
The	results	of	application	of	mushroom	DNA	in	bio­
therapy	of	mice	with	solid	Ehrlich	carcinoma	are	shown	
in	the	Table.	All	control	animals	developed	tumors	and	
died	within	52	days	(MST	33.8	±	4.4	days).	Mice	treated	
with	mushroom	DNA	in	prophylactic	regimen	of	appli­
cation	survived	till	80	days	(MST	was	46.3	±	8.4	days,	
and	ILS	—	37%).	Immunization	of	tumor­bearing	mice	
by	P. ostreatus DNA	 in	 therapeutic	 regimen	resulted	
in	a	dramatic	 increase	of	animal	survival	 rate:	MST	
was	71.0	±	8.6	days,	ILS	—	110%.	It	is	necessary	to	note	
that	one	animal	survived	till	110th	day	of	experiment.
Table. Results of biotherapeutic application of P. ostreatus DNA in mice 
with solid Ehrlich carcinoma
Group/treatment Number of ani-mals in group MST, days ILS, %
Control 9 33.8 ± 4.4 —
Prophylactic regimen 9 46.3 ± 8.4 37
Therapeutic regimen 10 71.0 ± 8.6 110
The	spectrum	of	detected	pharmacological	activities	
of	various	substances	isolated	from	P. ostreatus is	very	
broad.	However,	polysaccharides	are	the	best	known	
and	 the	most	potent	mushroom­derived	substances	
with	antitumor	and	 immunomodulating	properties	[6].	
It	was	reported	that	P. ostreatus mushrooms	possess	
potent	antitumor	activity	against	Ehrlich	ascites	carci­
noma	[7].	Oncoprotective	and	 immunomodulatory	ef­
fects	of	substances	from	P. ostreatus	were	demonstrated	
[21–23].	�esides,	P. ostreatus	diminishes	the	toxicity	of	
cyclophosphamide	in	mice	[24].	Antimutagenic	effects	
were	found	for	methanolic	extracts	of	P. ostreatus	[25].	
A	dried	mushroom	P. ostreatus	diet	reduced	pathological	
changes	in	dimethylhydrazine­induced	colon	cancer	in	
rats	but	did	not	influence	significantly	the	incidence	of	
tumors.	This	effect	is	explained	by	the	antioxidant	proper­
ties	of	this	mushroom	and	by	its	fiber	content	[26].	Also,	
a	pronounced	hypocholesteremic	effect	of	P. ostrea­
tus,	combined	with	inhibition	of	lipid	peroxydation,	was	
shown	in vivo.	Diet	including	10%	dried	fruiting	bodies	of	
P. ostreatus	significantly	reduced	the	incidence	and	size	
of	atherosclerotic	plaques	in	rabbits	[27].
In	the	present	study	biologically	active	mushroom	
product	was	isolated	and	characterized.	Obtained	data	
suggest	that	P. ostreatus	DNA	also	has	potent	immu­
nomodulatory	activity	similar	to	bacterial	DNA	or	DNA	
from	some	viruses,	yeast,	nematodes,	mollusks	and	
insects	and	in	contrast	to	various	vertebrates	(mam­
mals,	fish	and	frogs)	and	plants	(e.	g.,	corn)	DNA	which	
do	not	possess	immunogenic	activity	[11,	20,	28].
In	conclusion,	DNA	 isolated	 from	 fruit	bodies	of	
higher	�asidiomycetes	mushroom	P. ostreatus	pos­
sesses	immunomodulatory	activity	and	biotherapeu­
tic	potential	 that	probably	can	be	explained	by	 the	
presence	of	unmethylated	CpG	motifs.	�ased	on	the	
reported	results,	an	application	of	P. ostreatus	DNA	for	
cancer	biotherapy	is	a	promising	strategy.
Fig. 3. Survival	dynamics	of	tumor­bearing	mice	upon	applica­
tion	of	mushroom	DNA	(a	—	prophylactic	regimen,	b	—	thera­
peutic	regimen)
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